Piper Jaffray Reiterates Overweight on Vertex Pharmaceuticals (VRTX)

Piper Jaffray is out with its report today on Vertex Pharmaceuticals VRTX, reiterating Overweight. In a note to clients, Piper Jaffray writes, "We are attending the European Association for the Study of Liver meeting in Berlin where Late Breaker posters are up. Abstract #1363 on Vertex' Phase II quad combo trial of Telaprevir + HCV non-nuc polymerase inhibitor VX-222 showed 90% response at week 12. We saw even more impressive combination data on Pharmasset's HCV nucleotide polymerase inhibitors and Bristol-Myers' NS5A inhibitor BMS-790052 + protease inhibitor BMS-650032. VRTX shares may trade lower today, but we remain buyers into the April 28th AdComm as Telaprevir maintains a 2+ year over competition. We believe Vertex will use their strong balance sheet and equity capital to acquire HCV drugs." Piper Jaffray has a $52 PT on VRTX. At the time of posting, shares of VRTX were trading pre-market at $48.44, down 0.08% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CarePiper Jaffrayvertex pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!